Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15

Reuters

05-15

Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15

Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug $(IND.AU)$-enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451717-en) on May 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535007979"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535007979\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535007979?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535007979","market":"nz","top_or_hot":-1,"title":"Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a>-enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451717-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 04:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a>-enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451717-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5jKkl6:1","article_id":"2535007979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535007979","pubTimestamp":1747253712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug -enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4202":"服装、服饰与奢侈品","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SILO":"SILO PHARMA INC.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股"},"translate_title":"Silo Pharma聘请Veloxity Labs进行鼻内PTSD疗法SPC-15的IND研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SILO":0.9},"content_text":"Silo Pharma Engages Veloxity Labs for IND-Enabling Study of Intranasal PTSD Therapy SPC-15\n    \n\n        Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug $(IND.AU)$-enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451717-en) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}